换一批摘要Urothelial carcinoma(UC)is the 9th most common and the 13th most deadly cancer worldwide1.Despite the availability of platinum-based chemotherapy and immune checkpoint inhib-itors(ICIs),the 5-year survival rate of patients with metastatic UC(mUC)remains poor(10-15％)2.Antibody-drug conju-gates(ADCs),which combine tumor-specific monoclonal antibodies with cytotoxic agents,have emerged as a promising breakthrough.By targeting cancer cells and sparing healthy tis-sues,ADCs can overcome the key limitations of conventional treatments.
更多相关知识
- 浏览3
- 被引0
- 下载1
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
